MA29836B1 - FUSION PROTEINS WITH ALBUMIN - Google Patents

FUSION PROTEINS WITH ALBUMIN

Info

Publication number
MA29836B1
MA29836B1 MA30727A MA30727A MA29836B1 MA 29836 B1 MA29836 B1 MA 29836B1 MA 30727 A MA30727 A MA 30727A MA 30727 A MA30727 A MA 30727A MA 29836 B1 MA29836 B1 MA 29836B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
albumin fusion
albumin
vectors
host cells
Prior art date
Application number
MA30727A
Other languages
French (fr)
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
Craig Rosen
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MA29836B1 publication Critical patent/MA29836B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention englobe des protéines de fusion d'albumine. Les molécules d'acides nucléiques codant pour les protéines de fusion d'albumine de l'invention sont également englobées par l'invention, de même que les vecteurs contenant ces acides nucléiques, les cellules hôtes transformées avec ces vecteurs d'acides nucléiques, et les procédés de fabrication des protéines de fusion d'albumine de l'invention et utilisant ces acides nucléiques, vecteurs, et/ou cellules hôtes. De plus, la présente invention comprend des compositions pharmaceutiques comprenant les protéines de fusion d'albumine et les procédés de traitement, de prévention, ou d'amélioration de maladies, troubles pathologies utilisant les protéines de fusion d'albumine de l'invention.The present invention encompasses albumin fusion proteins. The nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and / or host cells. In addition, the present invention includes pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating disease, pathological conditions using the albumin fusion proteins of the invention.

MA30727A 2005-08-12 2008-03-07 FUSION PROTEINS WITH ALBUMIN MA29836B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15

Publications (1)

Publication Number Publication Date
MA29836B1 true MA29836B1 (en) 2008-10-03

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30727A MA29836B1 (en) 2005-08-12 2008-03-07 FUSION PROTEINS WITH ALBUMIN

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
JP2010503396A (en) * 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Albumin fusion protein
MX2009008230A (en) 2007-01-30 2010-03-08 Epivax Inc Regulatory t cell epitopes, compositions and uses thereof.
AU2009256547B2 (en) 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
EA023344B1 (en) 2009-01-16 2016-05-31 Тева Фармасьютикал Индастриз Лтд. Method for treating or preventing neutropenia or leukopenia or decreasing the incidence of infection as manifested by febrile neutropenia
JP5936112B2 (en) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ Albumin variants and complexes
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
CA2776241A1 (en) * 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
ES2674567T3 (en) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Bispecific Fusion Proteins
EP3189835B1 (en) * 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
CN104383541A (en) 2011-10-21 2015-03-04 艾伯维公司 Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
SE1450131A1 (en) 2011-10-21 2014-05-07 Abbvie Inc DAA combination therapy (eg with ABT-072 or ABT-333) for use in the treatment of HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104271150A (en) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (en) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
PT2882450T (en) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
DK3889173T3 (en) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc OPTIMIZED FACTOR VIII GENE
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
UY35463A (en) 2013-03-15 2014-10-31 Biogen Idec Inc FC-FACTOR IX POLYPEPTIDE FORMULATIONS IX.
MX2015016567A (en) 2013-06-28 2016-03-31 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof.
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
DK4176894T3 (en) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
EP3865147A1 (en) 2015-10-02 2021-08-18 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
PT3411478T (en) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Optimized factor viii genes
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2020500306A (en) 2016-11-04 2020-01-09 オーフス ウニベルシテット Identification and treatment of tumors characterized by neonatal Fc receptor overexpression
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
EP3548066A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MA47163A (en) 2016-12-16 2019-11-06 Biogen Ma Inc PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
TW201831521A (en) 2017-01-31 2018-09-01 美商生物化學醫療公司 Factor IX fusion proteins and methods of making and using same
CN110770251A (en) * 2017-04-20 2020-02-07 诺和诺德股份有限公司 Method for purifying albumin fusion proteins
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
BR112020015228A2 (en) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
MX2021001599A (en) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy.
WO2020118069A2 (en) 2018-12-06 2020-06-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CA3152600A1 (en) 2019-09-30 2021-04-08 Andrew KROETSCH Lentiviral vector formulations
JPWO2022030580A1 (en) * 2020-08-06 2022-02-10
JP2024056667A (en) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545090T3 (en) * 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
EP1594530A4 (en) * 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
MX2008001865A (en) 2008-04-15
JP2009504157A (en) 2009-02-05
IL189246A0 (en) 2008-08-07
CA2618476A1 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
NO20081233L (en) 2008-05-09
WO2007021494A3 (en) 2007-07-26
KR20080071119A (en) 2008-08-01
WO2007021494A2 (en) 2007-02-22
ECSP088262A (en) 2008-05-30
BRPI0614761A2 (en) 2009-05-19
AU2006280312A1 (en) 2007-02-22
EP1924596A2 (en) 2008-05-28
TNSN08064A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
MA29836B1 (en) FUSION PROTEINS WITH ALBUMIN
EP1841426A4 (en) Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
NO20054769L (en) Substituted phenylalkanoic acids
MX2009002816A (en) Albumin fusion proteins.
MA31862B1 (en) Antiseptic antibodies and their uses
EA200870019A1 (en) LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION
WO2004019878A3 (en) Adzymes and uses thereof
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
IL195338A (en) Antibody comprising an fc variant comprising d or e amino acid substitution at position 239 and pharmaceutical composition and use thereof
DE602005021072D1 (en) ADZYME AND ITS USES
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
TNSN07063A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
MA30085B1 (en) TREATMENT OF TYPE 2 DIABETES WITH AN ASSOCIATION OF DPIV INHIBITOR AND METFORMIN OR THIAZOLIDINEDIONE
MA30337B1 (en) ANTIBODY
DE602004014117D1 (en) THIAZOLE FOR USE AS INHIBITORS OF PROTEIN KINASES
MX2011006091A (en) Imidazopyrazine syk inhibitors.
ATE483692T1 (en) 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS BETA-SECRETASE (BACE) INHIBITORS
NO20054957L (en) Substituted carboxylic acids
WO2005077042A3 (en) Albumin fusion proteins
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE365733T1 (en) COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS
BRPI0407662B8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
MA30041B1 (en) IMMUNOGLOBULIN